GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (XSWX:ROG) » Definitions » Total Liabilities
中文

Roche Holding AG (XSWX:ROG) Total Liabilities

: CHF57,205 Mil (As of Dec. 2023)
View and export this data going back to 2001. Start your Free Trial

Roche Holding AG's Total Liabilities for the quarter that ended in Dec. 2023 was CHF57,205 Mil.

Roche Holding AG's quarterly Total Liabilities declined from Dec. 2022 (CHF56,136.00 Mil) to Jun. 2023 (CHF54,026.00 Mil) but then increased from Jun. 2023 (CHF54,026.00 Mil) to Dec. 2023 (CHF57,205.00 Mil).

Roche Holding AG's annual Total Liabilities declined from Dec. 2021 (CHF63,972.00 Mil) to Dec. 2022 (CHF56,136.00 Mil) but then increased from Dec. 2022 (CHF56,136.00 Mil) to Dec. 2023 (CHF57,205.00 Mil).


Roche Holding AG Total Liabilities Historical Data

The historical data trend for Roche Holding AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47,224.00 46,365.00 63,972.00 56,136.00 57,205.00

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63,972.00 57,790.00 56,136.00 54,026.00 57,205.00

Roche Holding AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Roche Holding AG's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=24824+(26091+1911
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+4379)
=57,205

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=90468-33263
=57,205

Roche Holding AG's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=24824+(26091+1911
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+4379)
=57,205

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=90468-33263
=57,205

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (XSWX:ROG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.